Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
The 50-issue NSE Nifty in range-bound movements settled higher by 59.15 points, or 0.58 per cent, at 10,252.10.
Investors were anxious concerned about the uncertainties over the timing of Us Federal Reserve rate hike, US policies under President Donald Trump, the upcoming French election and rising crude price that could impact inflation, going ahead. A weak closing in Asia tracking overnight losses in the US owing to all these unknowns triggered selling, brokers said.
The wider Nifty hit a low of 10,033.35 before finishing at 10,044.10, down 74.15 points or 0.73 per cent.
TCS, Wipro and Infosys dropped by up to 4.47 per cent, dragging down the BSE IT index by 2.96 per cent
The index rising for the fourth straight session surged 564 points.
HDFC, ONGC, Maruti Suzuki, HeroMoto Corp and Bajaj Auto gained the most on BSE Sensex
Maruti Suzuki fell 0.7% even after its March quarter profit grew by 15.8% to Rs 1,709 crore in Q4
The benchmark Sensex gained 4,642.84 points, or 16.%, while the broader NSE Nifty surged 1,572.85 points, or 18.20% during this period.
Gains were led by index heavyweights with Reliance Industries contributing the most.
Stocks reeled under huge losses on Thursday as the benchmark Sensex plunged sharply by over 465 points, the biggest single-day fall in three months, after India carried out "surgical strikes" on Wednesday night on terror launch pads across the Line of Control.
Sentiment was hurt after market regulator Sebi directed bourses to initiate action against 331 suspected shell companies.
Investors booked profits in recent gainers
The 30-share Sensex ended higher by 31 points at 26,591 and the 50-share Nifty gained 10 points at 8,061.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries:
The breadth, indicating strength of the market was strong
The broader NSE Nifty, after cracking below the key 10,300-mark, touched a low of 10,211.25, before finally ending 134.75 points, or 1.30 per cent, down at 10,226.55.
How did marquee Dalal Street investors fare in the Jan-Mar quarter that saw the BSE Sensex tank 10 per cent?
Foreign portfolio investors were net buyers in equities to the tune of Rs 119 crore, as per provisional stock exchange data.
The broader NSE Nifty too dived by 101.65 points, or 0.97 per cent, to close at 10,350.15.
Reliance Industries, Infosys and Tata Motors were the top contributors
On the sectoral map, consumer durables stayed in the lead by surging 2.39 per cent, followed by realty index, oil and gas and infra.
The Nifty rose 176.50 points, or 1.74 per cent, during the week.
Brokerages expect Nifty50 firms to post 11.8% growth in net profit in Q1 but sales may decline
Broader gains were capped as investors awaited corporate results from major firms
Sensex lacklustre, bluechips in focus.
Data also show that several other leading domestic pharma companies have recalled their products from the US
Top corporates have paid more advance tax in second quarter this year.
Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Of the 30-share Sensex pack, 22 ended with losses while NTPC ended flat at Rs 127.30.
Investors have kept their eyes on US-China trade talks and are optimistic about a positive outcome.
FMCG major ITC and private banking major ICICI Bank were the top Sensex losers
The S&P BSE Sensex dropped 207 points to end at 25,230.
Broader markets underperformed indices with BSE Midcap down 0.43% while the Smallcap index fell 0.07%.
With rate cut expectations running high ahead of RBI meet this week, risk appetite improved especially in rate sensitive stocks
Sun Pharma was by far the biggest gainer in the Sensex pack, surging 8.13 per cent, followed by Dr Reddy's at 4.92 per cent.
The sentiment got support from better-than-expected earning results by select companies and continuous buying by domestic financial institutions.
Is yet to decide about the partnership or acquisition route
